ABSTRACT
Protein–protein interactions are crucial for cellular homeostasis and play important roles in the dynamic execution of biological processes. While antibodies represent a well-established tool to study protein interactions of extracellular domains and secreted proteins, as well as in fixed and permeabilized cells, they usually cannot be functionally expressed in the cytoplasm of living cells. Non-immunoglobulin protein-binding scaffolds have been identified that also function intracellularly and are now being engineered for synthetic biology applications. Here we used the Designed Ankyrin Repeat Protein (DARPin) scaffold to generate binders to fluorescent proteins and used them to modify biological systems directly at the protein level. DARPins binding to GFP or mCherry were selected by ribosome display. For GFP, binders with KD as low as 160 pM were obtained, while for mCherry the best affinity was 6 nM. We then verified in cell culture their specific binding in a complex cellular environment and found an affinity cut-off in the mid-nanomolar region, above which binding is no longer detectable in the cell. Next, their binding properties were employed to change the localization of the respective fluorescent proteins within cells. Finally, we performed experiments in Drosophila melanogaster and Danio rerio and utilized these DARPins to either degrade or delocalize fluorescently tagged fusion proteins in developing organisms, and to phenocopy loss-of-function mutations. Specific protein binders can thus be selected in vitro and used to reprogram developmental systems in vivo directly at the protein level, thereby bypassing some limitations of approaches that function at the DNA or the RNA level.
Footnotes
↵* These authors contributed equally to this work
↵‡ These authors contributed equally to this work
Author Contributions M.B., S.H., A.P. and M.A. conceived and designed the experiments. M.B., S.H., E.C., A.L., A.O.-E., O.S. and S.G.S. performed the experiments and analysed the data. M.B., S.H., A.P. and M.A. wrote paper.
Competing interests The authors have no competing interests to declare. A.P. is a cofounder and shareholder of Molecular Partners AG, commercializing the DARPin technology.
- Received August 26, 2014.
- Accepted October 11, 2014.
- © 2014. Published by The Company of Biologists Ltd
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
Keywords
Article Navigation
Related articles
Cited by...
More in this TOC section
Similar articles
Other journals from The Company of Biologists
Cover article - Apolipoprotein L9 interacts with LC3/GABARAP and is a microtubule-associated protein with a widespread subcellular distribution
Arvind A. Thekkinghat, Kamlesh K. Yadav and Pundi N. Rangarajan demonstrate the versatile properties of apolipoprotein L9, a lipid-binding protein, and its influence on a variety of activities taking place inside an animal cell.
James J. Dowling and his colleagues conducted the first large-scale screening efforts for NEBLUN-related nemaline myopathy to address the urgent need for effective treatment for patients affected by the disease.
Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Arvind Thekkinghat, Shannon Taylor and Daisuke Takao.
Biology Open has strong credentials and publishing with us is easy and fast. BiO aims to provide rapid publication for scientifically sound observations and valid conclusions in developmental, cell, experimental and translational biology. Submit your paper here – you’ll be in good company!
Recent developmental biology highlights in BiO – Anna Nele Herdina and her colleagues define the spectrum of phenotypic abnormalities linked with Col4a2 disruption, and demonstrate the opportunities the Deciphering the Mechanisms of Developmental Disorders (DMDD) program offers for exploring rare human diseases.
Transfer to Biology Open
Did you know: if your submission to one of our sister journals, Development, Journal of Cell Science, Journal of Experimental Biology or Disease Models & Mechanisms, is unsuccessful, you can transfer your paper and any reviews directly to Biology Open. The majority of papers transferred with reviews are accepted for publication. Read here to find out more.
BiO partners with Publons.
Biology Open is pleased to announce a new partnership with Publons. This allows reviewers to easily track and verify every review by choosing to add the review to their Publons profile when completing the review submission form. Publons makes it simple for reviewers to showcase their peer review contributions in a format that can be included in job and funding applications (without breaking reviewer anonymity). Read the official announcement here!
preLights - preLights reaches 500 posts!
The success of preLights is down to the hard work of our preLighters. Head over to the preLights website to find out more about our most active early-career researchers.